Edwards Lifesciences Corporation
Edwards Lifesciences Appoints Theodora Mistras as New CFO
Summary
Edwards Lifesciences Corporation announced on May 4, 2026, the appointment of Theodora ('Doretta') Mistras as its new Corporate Vice President and Chief Financial Officer, effective May 29, 2026. Mistras, previously CFO of Viatris, Inc., brings extensive experience in global finance leadership. She will succeed Scott Ullem, who has been CFO since 2014. Mistras' compensation includes an annual base salary of $925,000, a target annual bonus of at least 100% of her base salary, a sign-on bonus of $2,013,000, and restricted stock units valued at $8,000,000. The appointment is part of a planned transition, with Ullem continuing as a strategic advisor.
Profitelligence Alerts
Get alerts for EW
Be first to know when Edwards Lifesciences Corporation files with the SEC.
Filing Categories
Advertisement
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.
Official SEC Documents
Advertisement